(CNTA) Centessa Pharmaceuticals - Ratings and Ratios
Serpin, OXER1, Vasopressin, Platelet, Kidney
Description: CNTA Centessa Pharmaceuticals
Centessa Pharmaceuticals PLC ADR (NASDAQ:CNTA) is a biotechnology company listed on the NASDAQ stock exchange, originating from the United Kingdom. The companys stock is classified under the GICS Sub Industry of Biotechnology.
The stocks recent performance indicates a market capitalization of approximately $2.15 billion USD, with an average trading volume of over 1 million shares. The absence of a Price-to-Earnings (P/E) ratio, both current and forward, suggests that the company is currently unprofitable, which is not uncommon for companies in the biotechnology sector, particularly those focused on research and development.
A key driver for CNTAs stock performance will be its ability to progress through clinical trials and obtain regulatory approvals for its drug candidates. The Return on Equity (RoE) of -65.75% underscores the significant investment in research and development, highlighting the companys growth stage and the inherent risks associated with the biotechnology industry.
From a trading perspective, the stocks beta of 1.485 indicates a higher volatility compared to the overall market, suggesting that investors should be prepared for potentially significant price swings. The stocks current price is near its 52-week high, having more than doubled from its 52-week low, indicating a strong recent performance.
To evaluate the investment potential of CNTA, key performance indicators (KPIs) to monitor include the progress of its pipeline assets, cash burn rate, and any upcoming milestones such as clinical trial results or regulatory decisions. Economic drivers influencing the stocks performance will include overall market sentiment towards biotechnology stocks, interest rate changes affecting the cost of capital, and broader healthcare industry trends.
CNTA Stock Overview
| Market Cap in USD | 2,417m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-05-28 |
CNTA Stock Ratings
| Growth Rating | 52.5% |
| Fundamental | 31.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 9.15% |
| Analyst Rating | 4.64 of 5 |
CNTA Dividends
Currently no dividends paidCNTA Growth Ratios
| Growth Correlation 3m | 87.3% |
| Growth Correlation 12m | -16.6% |
| Growth Correlation 5y | 22.5% |
| CAGR 5y | 67.80% |
| CAGR/Max DD 3y | 1.55 |
| CAGR/Mean DD 3y | 4.51 |
| Sharpe Ratio 12m | -0.07 |
| Alpha | 0.23 |
| Beta | 0.124 |
| Volatility | 63.09% |
| Current Volume | 1159.2k |
| Average Volume 20d | 1081.9k |
| Stop Loss | 20.2 (-5.3%) |
| Signal | -1.42 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-230.4m TTM) > 0 and > 6% of Revenue (6% = 957.1k TTM) |
| FCFTA -0.29 (>2.0%) and ΔFCFTA 11.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1697 % (prev 4755 %; Δ -3059 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.29 (>3.0%) and CFO -143.9m > Net Income -230.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (133.7m) change vs 12m ago 22.09% (target <= -2.0% for YES) |
| Gross Margin 92.72% (prev 86.10%; Δ 6.62pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 3.58% (prev 1.73%; Δ 1.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -19.93 (EBITDA TTM -214.2m / Interest Expense TTM 10.8m) >= 6 (WARN >= 3) |
Altman Z'' -14.28
| (A) 0.55 = (Total Current Assets 300.4m - Total Current Liabilities 29.7m) / Total Assets 492.1m |
| (B) -2.16 = Retained Earnings (Balance) -1.07b / Total Assets 492.1m |
| warn (B) unusual magnitude: -2.16 — check mapping/units |
| (C) -0.48 = EBIT TTM -215.1m / Avg Total Assets 445.5m |
| (D) -7.22 = Book Value of Equity -1.06b / Total Liabilities 147.2m |
| Total Rating: -14.28 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.30
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -6.24% = -3.12 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.32 = 2.45 |
| 5. Debt/Ebitda -0.52 = -2.50 |
| 6. ROIC - WACC (= -48.56)% = -12.50 |
| 7. RoE -56.47% = -2.50 |
| 8. Rev. Trend 36.29% = 2.72 |
| 9. EPS Trend 14.95% = 0.75 |
What is the price of CNTA shares?
Over the past week, the price has changed by +2.30%, over one month by +21.26%, over three months by +69.29% and over the past year by +29.59%.
Is Centessa Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CNTA is around 21.44 USD . This means that CNTA is currently overvalued and has a potential downside of 0.52%.
Is CNTA a buy, sell or hold?
- Strong Buy: 7
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CNTA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.4 | 52% |
| Analysts Target Price | 32.4 | 52% |
| ValueRay Target Price | 23.4 | 9.5% |
Last update: 2025-09-10 04:34
CNTA Fundamental Data Overview
CCE Cash And Equivalents = 250.7m USD (Cash And Short Term Investments, last quarter)
P/S = 161.1558
P/B = 7.0123
Beta = 1.481
Revenue TTM = 16.0m USD
EBIT TTM = -215.1m USD
EBITDA TTM = -214.2m USD
Long Term Debt = 109.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.31m USD (from shortTermDebt, last quarter)
Debt = 110.9m USD (Calculated: Short Term 1.31m + Long Term 109.5m)
Net Debt = 73.9m USD (from netDebt column, last quarter)
Enterprise Value = 2.28b USD (2.42b + Debt 110.9m - CCE 250.7m)
Interest Coverage Ratio = -19.93 (Ebit TTM -215.1m / Interest Expense TTM 10.8m)
FCF Yield = -6.24% (FCF TTM -142.1m / Enterprise Value 2.28b)
FCF Margin = -890.7% (FCF TTM -142.1m / Revenue TTM 16.0m)
Net Margin = -1444 % (Net Income TTM -230.4m / Revenue TTM 16.0m)
Gross Margin = 92.72% ((Revenue TTM 16.0m - Cost of Revenue TTM 1.16m) / Revenue TTM)
Tobins Q-Ratio = -2.14 (set to none) (Enterprise Value 2.28b / Book Value Of Equity -1.06b)
Interest Expense / Debt = 2.60% (Interest Expense 2.88m / Debt 110.9m)
Taxrate = 21.0% (US default)
NOPAT = -215.1m (EBIT -215.1m, no tax applied on loss)
Current Ratio = 10.12 (Total Current Assets 300.4m / Total Current Liabilities 29.7m)
Debt / Equity = 0.32 (Debt 110.9m / last Quarter total Stockholder Equity 344.9m)
Debt / EBITDA = -0.52 (Net Debt 73.9m / EBITDA -214.2m)
Debt / FCF = -0.78 (Debt 110.9m / FCF TTM -142.1m)
Total Stockholder Equity = 408.0m (last 4 quarters mean)
RoA = -46.81% (Net Income -230.4m, Total Assets 492.1m )
RoE = -56.47% (Net Income TTM -230.4m / Total Stockholder Equity 408.0m)
RoCE = -41.57% (Ebit -215.1m / (Equity 408.0m + L.T.Debt 109.5m))
RoIC = -42.28% (NOPAT -215.1m / Invested Capital 508.8m)
WACC = 6.28% (E(2.42b)/V(2.53b) * Re(6.47%)) + (D(110.9m)/V(2.53b) * Rd(2.60%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 3.22%
Discount Rate = 6.47% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -142.1m)
EPS Correlation: 14.95 | EPS CAGR: 19.04% | SUE: -0.25 | # QB: 0
Revenue Correlation: 36.29 | Revenue CAGR: 0.0% | SUE: N/A | # QB: None
Additional Sources for CNTA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle